ORAMED PHARMACEUTICALS INC.(ORMP)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

ORAMED PHARMACEUTICALS INC. (ORMP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ORMP at 44.4/100 on a 32-signal composite quality model, placing it at rank #1,922 of 2,962 stocks — the bottom half of the AI-ranked universe. ORMP scores in the top quartile across profitability (100.0), balance sheet strength (99.8), institutional flow (86.6). Areas of concern include revenue scale (1.5) and free cash flow (3.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.5/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of ORMP by reported 13-F value include MERCER GLOBAL ADVISORS, Aquamarine Financial (Cayman) Ltd, Gem Investment Advisors, based on the most recent SEC filings. ORMP trades on the Nasdaq exchange and files with the SEC under CIK 1176309. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ORMP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ORAMED PHARMACEUTICALS INC. directly from SEC EDGAR.